Carlton Hofferkamp & Jenks Wealth Management LLC Sells 356 Shares of Johnson & Johnson (NYSE:JNJ)

Carlton Hofferkamp & Jenks Wealth Management LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,061 shares of the company’s stock after selling 356 shares during the quarter. Johnson & Johnson makes up approximately 0.9% of Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings, making the stock its 28th biggest holding. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,485,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. IFS Advisors LLC boosted its position in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after acquiring an additional 100 shares during the last quarter. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at approximately $32,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson during the third quarter worth about $35,000. Activest Wealth Management acquired a new position in shares of Johnson & Johnson during the third quarter worth $40,000. Finally, Fiduciary Advisors Inc. acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $43,000. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Down 0.1 %

Johnson & Johnson stock opened at $165.22 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a fifty day moving average of $152.11 and a 200 day moving average of $156.19. The stock has a market cap of $397.79 billion, a PE ratio of 24.85, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the previous year, the company earned $2.29 EPS. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on JNJ shares. Guggenheim lifted their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday, February 3rd. Raymond James lowered their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Wolfe Research assumed coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Stifel Nicolaus reduced their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Finally, Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.